Insulin resistance - type B

Last update 08 May 2025

Basic Info

Synonyms

Insulin resistance - type B, Insulin resistance - type B (disorder), Insulin resistance syndrome, Type B

+ [7]

Introduction

A rare genetic disease that belongs to the group of extreme insulin-resistance syndromes and is due to autoantibodies directed against insulin receptor.

Clinical Trials associated with Insulin resistance - type B

ACTRN12613000706774

/ RecruitingNot ApplicableIIT

Does undercarboxylated osteocalcin contribute to improved insulin sensitivity following exercise in overweight and obese men?

Start Date03 Sep 2012

Sponsor / Collaborator

Victoria University

100 Clinical Results associated with Insulin resistance - type B

100 Translational Medicine associated with Insulin resistance - type B

0 Patents (Medical) associated with Insulin resistance - type B

146

Literatures (Medical) associated with Insulin resistance - type B

01 Apr 2025·Diabetes Care

New Therapeutic Perspectives in Type B Insulin Resistance Syndrome: Efficacy of a Multitarget Therapy With Obinutuzumab and Mycophenolate Mofetil in Two Patients With Insulin Receptor Autoantibodies and Systemic Lupus Erythematosus

Letter

Author: Abisror, Noémie ; Hadjadj, Jérôme ; Vatier, Camille ; Jachiet, Vincent ; Auclair, Martine ; Vigouroux, Corinne ; Fain, Olivier ; Vuillaume, Philippine

01 Sep 2024·Diabetes & Metabolism

Type B insulin resistance syndrome: A case report

Letter

Author: Vigouroux, Corinne ; Auclair, Martine ; Garcia, Cyril ; Lamand, Virginie ; Nassouri, Sika ; Sollier, Mathilde ; Bordier, Lyse ; Caré, Weniko ; Duckett, Katie

TBIRS is most observed in young women of African origin.A history of autoimmune disorder is common, usually systemic lupus erythematosus or mixed connective tissue disease.TBIRS can also occur in association with type 1 diabetes or as a paraneoplastic manifestation (e.g. lymphoproliferative disorders).TBIRS is a very rare disease, with only about a hundred cases.We report a new case observed in France in a young woman.A 23-yr-old female of Guinean origin, with no personal or family medical history, presented with polydipsia, secondary amenorrhea, and weight loss (15 % of body weight; body mass index 24.1 kg/m2).Phys. examination revealed severe acanthosis nigricans on the neck, axillae, and thighs.Extremely high doses of insulin (up to 500 units/h) for several days were required to maintain blood glucose level < 200 mg/dL and normalize ketones level.The following treatment regimen was used: human ultraconcd. insulin to facilitate administration of very large doses, dexamethasone 40 mg/d for 4 days, 3 times at one-month intervals, and one cycle of rituximab (two infusions at fortnightly interval at the dose of 750 mg/m2).Insulin doses increased following glucocorticoid therapy but decreased in a few days allowing infusion to be discontinued.Metformin and glucagon-like peptide 1 (GLP-1)-receptor agonist were used in association with insulin therapy to decrease insulin resistance.Over a6-mo period, we observed a decrease in insulin doses until normalization of blood glucose levels, as well as remission of acanthosis nigricans and signs of hyperandrogenism.The time course of the interstitial glucose time-in-range (70-180 mg/dL), monitored with a FreeStyle device (Abbott diabetes care Inc., USA), during follow-up, and the treat ment regimen are presented in the Fig. 1.In this case, we decided not to use cyclophosphamide because of the patient's young age and the risk of toxicity (mainly gonadal).Some elements remain unexplained, such as the discrepancy be tween high doses of insulin and absence of hypokalemia as well as significant ketosis without symptoms or acidosis.

01 Sep 2024·Journal of Diabetes

Type B insulin resistance syndrome induced by anti‐PD‐1 therapy

Letter

Author: Shi, Xiaomin ; Zhang, Huabing ; Wu, Chaoming ; Zhou, Yingying ; Li, Ming ; He, Mengyu ; Shi, Mengte ; Ni, Li ; Dai, Zhijuan

A 59-yr-old man was diagnosed with Hodgkin lymphoma in May 2020 and began treatment with sintilimab in August 2020.The patient had a normal blood glucose test before receiving treatment with sintilimab, with no family history of diabetes.In Sept. 2020, the patient developed diabetic ketoacidosis after receiving three cycles of sintilimab. Glycated Hb A1c (HbA1c) was 7.0%, and C-peptide level was undetectable.Diabetes-related antibodies, including glutamic acid decarboxylase antibody, insulinoma-associated protein 2 antibodies, and insulin autoantibodies, were all neg.Based on these findings, he was diagnosed with fulminant type 1 diabetes caused by anti-programmed cell death-1 (anti-PD-1) therapy.Addnl., he was also diagnosed with destructive thyroiditis caused by antiPD-1 therapy at the same time.After discharge, he received insulin therapy, and his glucose level fluctuated between 4 and 20 mmol/L. The treatment regimen for Hodgkin′s lymphoma was modified, and sintilimab treatment was stopped.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Insulin resistance - type B

Basic Info

Related

Analysis